Emergency Medicine International
Volume 2018 (2018), Article ID 4642127, 9 pages
https://doi.org/10.1155/2018/4642127

Research Article

Clinical Effects of Activated Charcoal Unavailability on Treatment Outcomes for Oral Drug Poisoned Patients

Sohyun Park,¹ Hui Jai Lee,¹ Jonghwan Shin,¹ Kyoung Min You,¹ Se Jong Lee,² and Euigi Jung³

¹Department of Emergency Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul 07061, Republic of Korea
²Department of Emergency Medicine, Sejong General Hospital, Bucheon, Gyeonggi-do 14754, Republic of Korea
³Department of Emergency Medicine, Central Veterans Hospital, Seoul 05368, Republic of Korea

Correspondence should be addressed to Hui Jai Lee; emdrlee@gmail.com

Received 26 May 2018; Revised 27 August 2018; Accepted 19 September 2018; Published 3 October 2018

Academic Editor: Marco L. A. Sivilotti

Copyright © 2018 Sohyun Park et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Background. Activated charcoal is the most frequently and widely used oral decontaminating agent in emergency departments (EDs). However, there is some debate about its clinical benefits and risks. In Korea, activated charcoal with sorbitol was unavailable as of the mid-2015, and our hospital had been unable to use it from September 2015. This study examined the differences of clinical features and outcomes of patients during the periods charcoal was and was not available. Methods. We retrospectively reviewed the electronic medical records of patients who had visited an urban tertiary academic ED for oral drug poisoning between January 2013 and January 2017. Results. For the charcoal-available period, 413 patients were identified and for the charcoal-unavailable period, 221. Activated charcoal was used in the treatment of 141 patients (34%) during the available period. The mortality rates during the available and unavailable periods were 1.9 and 0.9%, respectively (p = 0.507). There was also no interperiod difference in the development of aspiration pneumonia (9.9 versus 9.5%, p = 0.864), the endotracheal intubation rate (8.4 versus 7.2%, p = 0.586), and vasopressor use (5.3 versus 5.0%, p = 0.85). Intensive care unit (ICU) admission was higher in the unavailable period (5.8 versus 13.6%, p = 0.001). ICU days were lower in the unavailable period (10 [4.5-19] versus 4 [3-9], p = 0.01). Hospital admission (43.3 versus 29.9%, p = 0.001) was lower in the unavailable period. Conclusions. In this single center study, there appeared to be no difference in mortality, intubation rates, or vasopressor use between the charcoal-available and charcoal-unavailable periods.

1. Introduction

Activated charcoal is the gastrointestinal (GI) decontaminating agent that had been regarded as an essential first-line therapy for acute-poisoning patients. However, few studies have shown clinical improvement of poisoned patients who had been treated using activated charcoal. Indications of activated charcoal are decreasing. The indications and use of activated charcoal as a decontamination procedure actually have been declining over the years [1–3]. American poison centers reported a sharp drop between 1995 and 2016, from 7.7% of all exposures to 1.9%, respectively [4]. The most recent guidelines emphasize that activated charcoal should not be used routinely [5]. However, there are as yet no specific and detailed guidelines on the use of activated charcoal. Indeed, there are significant variations in the use of activated charcoal among clinicians [6, 7].

In Korea, premixed activated charcoal with sorbitol had been the only available form of activated charcoal [8]. Due to importation issue, its use was discontinued from 2015. As a result, activated charcoal with sorbitol has been unavailable at our hospital from September of that year. In the present study, we evaluated the clinical outcome differences between the charcoal-available and charcoal-unavailable periods.

2. Materials and Methods

2.1. Study Design and Setting

This study was conducted in an urban academic teaching hospital with an annual emergency department (ED) census of 58000. A retrospective chart review was conducted for the period from January 2013 to January 2017. Patients whose ICD-10-based ED diagnosis was poison-related were selected from electronic medical records. Those who had visited the ED with oral drug overdose, were over 18 years old, and had been exposed within the previous 24 hours were included. Those aged under 18 years, pregnant women, and those suffering caustic ingestion or heavy metal poisoning were excluded.

The subjects’ age, sex, clinical parameters such as vital signs, Glasgow Coma Scale (GCS), underlying diseases, laboratory results, and clinical outcomes were collected. Aspiration pneumonia was defined as newly developed lung lesions on chest X-ray or computed tomography and worsening of respiratory symptoms within 48 hours of admission [9, 10].

This study was approved by the Institutional Review Board (IRB) of the study hospital (IRB no. 20170626/30-2017-15/073). Informed consent was waived by the IRB.

2.2. Statistical Analysis

Mortality, endotracheal intubation and vasopressor use, development of aspiration pneumonia, intensive care unit (ICU) admission, and hospital admission were evaluated as clinical outcomes.

A subgroup analysis was performed for factors that can affect the clinical efficacy of activated charcoal based on previous studies [11–13]. Moreover, we defined the conditions under which activated charcoal can be beneficial: (1) patient presents within 2 hours of ingestion, (2) GCS 13-15 on arrival, and (3) potentially toxic ingestion (excluding ingestion of less toxic substance such as benzodiazepines and sedatives, as well as cases of ingestion of relatively small amounts) [5]. Two board-certified emergency physicians decide whether there is potential toxic exposure or not.

The Shapiro-Wilk test was used to evaluate the normality of the continuous variables, which were expressed as a mean ± standard deviation or median (interquartile range), as appropriate. Categorical variables were summarized by frequency according to the corresponding percentage and compared using the chi-square test or Fisher’s exact test as appropriate.

All of the analyses were performed with SPSS 22 (IBM, Armonk, New York, USA). A p value less than 0.05 was considered to indicate statistical significance.

3. Results

3.1. Characteristics of the Patients

In this retrospective cohort study, we identified 634 patients who met the study criteria. Four hundred and thirteen (413) patients were managed during the activated charcoal-available period and 221 during the activated charcoal-unavailable period (Table 1). Activated charcoal was used in the treatment of 141 patients (34.0%) during the activated charcoal-available period. No enrolled patient received multiple-dose charcoal.

Table 1: Patient characteristics.

Charcoal-available period
Charcoal-unavailable period
p-value

(n=413)
(n=221)

Age, median (IQR)
41 (28-58)
43
0.267

Male, n (%)
148 (35.8%)
77
0.803

Medical History

    Hypertension, n (%)
72 (17.4%)
32 (14.5%)
0.339

    Diabetes mellitus, n (%)
40 (9.7%)
19 (8.6%)
0.653

Multiple drug ingestion
242 (58.6%)
119 (53.8%)
0.250

Vital signs

    Mean blood pressure (mmHg), median (IQR)
93 (79-103)
94 (77-107)
0.495

    Heart rate (/min), median (IQR)
90 (79-100)
87 (76-103)
0.258

    Respiratory rate (/min), median (IQR)
20 (18-20)
20 (18-20)
0.168

    Body temperature (°C), median (IQR)
36.2 (36.0-36.6)
36.4 (36.0-36.7)
0.102

GCS, median (IQR)
14 (11-15)
14 (10-15)
0.971

Laboratory results

    WBC (x10³/μℓ), median (IQR)
7.55 (5.76-10.19)
7.44 (5.96-9.82)
0.996

    Hemoglobin (g/dℓ), median (IQR)
13.5 (12.6-14.6)
13.4 (12.2-14.6)
0.374

    Platelet (1000/μℓ), median (IQR)
249 (205.5-299.5)
249 (202-298.5)
0.970

    Sodium (mmol/ℓ), median (IQR)
139.1 (137.3-140.9)
138.6 (136.6-140.6)
0.046

    Potassium (mmol/ℓ), median (IQR)
3.8 (3.54-4.12)
3.8 (3.50-4.00)
0.429

    Total CO₂ (mmol/ℓ), median (IQR)
22.8 (20.90-26.26)
22.3 (20.15-26.50)
0.082

    BUN (mg/dℓ), median (IQR)
12 (9-16)
13 (11-16)
0.167

    Creatinine (mg/dℓ), median, (IQR)
0.74 (0.61-0.89)
0.74 (0.65-0.91)
0.242

    AST (IU/ℓ), median, (IQR)
25 (19-37)
25 (19-28)
0.880

    ALT (IU/ℓ), median, (IQR)
15 (10-25)
15 (10-29)
0.772

    CRP (mg/dℓ), median, (IQR)
0.08 (0.03-0.24)
0.07 (0.02-0.26)
0.501

    CK (IU/ℓ), median, (IQR)
97 (69-151)
96 (68-159)
0.838

    CK-MB (ng/mL), median (IQR)
0.5 (0.5-1.1)
0.9 (0.6-2.1)
< 0.001

    Troponin I (ng/mL), median (IQR)
0.04 (0.04-0.04)
0.02 (0.01-0.02)
< 0.001

    aPTT (seconds), median (IQR)
25.9 (23.0-28.7)
27.2 (25.0-30.3)
< 0.001

    PT (INR), median (IQR)
1.06 (1.01-1.11)
1.06 (1.01-1.12)
0.836

Gastric lavage, n (%)
109 (26.4%)
22 (10%)
< 0.001

Activated charcoal, use n (%)
141 (34.1%)
0 (0%)
< 0.001

SOFA score
6 (4-7)
5 (3-6)
0.153

GCS: Glasgow Coma Scale; WBC: white blood cells; BUN: blood urea nitrogen; AST: aspartate transaminase; ALT: alanine aminotransferase; CRP: C-reactive protein; CK: creatine kinase; CK-MB: creatine kinase-MB; aPTT: activated partial thromboplastin time; PT: prothrombin time; SOFA: sequential organ failure assessment.

Only for ICU patients.

There was no interperiod difference in patient age, sex, medical history, or vital signs. There were statistical interperiod differences in some initial laboratory values (sodium, creatine kinase-MB, troponin I, and activated partial thromboplastin time) (Table 1), though they were minimal and not clinically significant. Gastric lavage was more frequently performed in the activated charcoal-available period (26.4%) than in the activated charcoal-unavailable period (10%) (p < 0.001). The ingested toxic substances of both groups are presented in Table 2.

Table 2: Toxic substances ingested by patients.

Charcoal-available period
Charcoal-unavailable period

CNS Affecting Drug, n (%)
134 (32.4%)
77 (34.8%)

Benzodiazepine, n (%)
21 (5.1%)
8 (3.6%)

Acetaminophen, n (%)
16 (3.9%)
8 (3.6%)

Cardiovascular drug, n (%)
4 (1.0%)
4 (1.8%)

Salicylate, n (%)
6 (1.5%)
1 (0.5%)

OTC drugs, n (%) †
9 (2.2%)
7 (3.2%)

Two or more toxin types, n (%)
132 (32.0%)
73 (33.0%)

Others, n (%)
51 (12.3%)
26 (11.8%)

Unknown, n (%)
40 (9.7%)
17 (7.7%)

CNS: central nervous system; OTC: over the counter.

Except benzodiazepine.

†Substances not clearly identified.

3.2. Charcoal Availability and Clinical Outcome

There were no differences in the incidence of aspiration pneumonia, the rate of intubation, vasopressor use, or mortality between the charcoal-available and charcoal-unavailable periods (Table 3).

Table 3: Charcoal availability and clinical outcome.

Charcoal-available period
Charcoal-unavailable period
p-value

Aspiration pneumonia, n (%)
41 (9.9%)
21 (9.5%)
0.864

Endotracheal intubation, n (%)
35 (8.5%)
16 (7.2%)
0.586

Vasopressor, n (%)
22 (5.3%)
11 (5.0%)
0.850

Mortality, n (%)
8 (1.9%)
2 (0.9%)
0.507

Hospital admission, n (%)
179 (43.3%)
66 (29.9%)
<0.001

ICU admission, n (%)
24 (5.8%)
30 (13.6%)
<0.001

ICU: intensive care unit.

The rates of hospital admission (43.3 versus 29.9%, p < 0.001) and ICU admission (5.8 versus 13.6%, p < 0.001) were higher in the charcoal-unavailable period; however, the number of ICU days was lower and the total hospital stay was shorter (Table 3 and Figure 1).

Figure 1: Length of stay of patients admitted to ICU between charcoal-available and charcoal-unavailable periods.   extreme outlier case is present in charcoal-unavailable period (41 ICU days and 91 total hospital days).

3.3. GCS and Clinical Outcomes according to Charcoal Availability

According to the GCS levels, there were no interperiod differences in aspiration pneumonia, intubation, vasopressor use, or mortality. In the charcoal-unavailable period, hospital admission was less common and the rate of ICU admission was higher for patients with preserved mental status (GCS 13-15) (Table 3). During the charcoal-available period, both hospital admission and ICU admission were more common for charcoal-administered patients (Table 4).

Table 4: GCS and clinical outcomes compared between charcoal-available and charcoal-unavailable periods.

Charcoal-available period
Charcoal-unavailable period
p-value†

Non-charcoal
Charcoal
Total
p-value

Aspiration pneumonia

    GCS 13-15
7 (4.0%)
7 (7.4%)
14 (5.2%)
0.258
3 (2.1%)
0.119

    GCS 9-12
7 (13.7%)
3 (10.7%)
10 (12.7%)
>0.990
4 (10.8%)
>0.999

    GCS 3-8
14 (29.2%)
3 (15.8%)
17 (25.4%)
0.356
14 (36.8%)
0.216

Intubation

    GCS 13-15
3 (1.7%)
6 (6.4%)
9 (3.4%)
0.071
3 (2.1%)
0.552

    GCS 9-12
5 (9.8%)
4 (14.3%)
9 (11.4%)
0.713
3 (8.1%)
0.749

    GCS 3-8
9 (18.8%)
8 (47.1%)
17 (25.4%)
0.064
10 (26.3%)
0.915

Vasopressor use

    GCS 13-15
7 (4.0%)
3 (3.2%)
10 (3.7%)
>0.990
5 (3.4%)
0.868

    GCS 9-12
4 (7.8%)
1 (3.6%)
5 (6.3%)
0.651
1 (2.7%)
0.663

    GCS 3-8
6 (12.5%)
1 (5.3%)
7 (10.4%)
0.663
5 (13.2%)
0.753

Mortality

    GCS 13-15
3 (1.7%)
1 (1.1%)
4 (1.5%)
>0.990
1 (0.7%)
0.660

    GCS 9-12
1 (2.0%)
0 (0%)
1 (1.3%)
>0.990
1 (2.7%)
0.538

    GCS 3-8
3 (6.3%)
0 (0%)
3 (4.5%)
0.553
0 (0%)
0.552

Hospital admission

    GCS 13-15
50 (28.9%)
39 (41.5%)
89 (33.3%)
0.037
28 (19.2%)
0.002

    GCS 9-12
26 (51.0%)
17 (60.7%)
43 (54.4%)
0.046
15 (40.5%)
0.163

    GCS 3-8
36 (75.6%)
11 (57.9%)
47 (70.1%)
0.168
23 (60.5%)
0.315

ICU admission

    GCS 13-15
2 (1.2%)
6 (6.4%)
8 (3.0%)
0.024
12 (8.2%)
0.028

    GCS 9-12
3 (5.9%)
2 (7.1%)
5 (6.3%)
>0.990
6 (16.2%)
0.102

    GCS 3-8
7 (14.6%)
4 (21.1%)
11 (16.4%)
0.492
12 (31.6%)
0.071

Number of patients

    GCS 13-15
173
94
267

146

    GCS 9-12
51
28
79

37

    GCS 3-8
48
19
67

38

GCS: Glasgow Coma Scale; ICU: intensive care unit.

noncharcoal and charcoal.

†Between charcoal-available and charcoal-unavailable periods.

3.4. Single- and Multiple-Drug Ingestions and Clinical Outcome according to Activated Charcoal Availability

Higher hospital admission rates and lower ICU admission rates during the charcoal-unavailable period were observed among the single-drug-poisoned patients. The other clinical outcomes did not differ between the periods for either single- or multiple-drugs-poisoned patients (Table 5).

Table 5: Multiple-drug ingestion and clinical outcomes compared between charcoal-available and charcoal-unavailable periods.

Charcoal-available period
Charcoal -unavailable period
p-value†

Non-Charcoal
Charcoal
Total
P

Aspiration pneumonia

    single drug
11 (9.9%)
8 (13.3%)
19 (11.1%)
0.497
11 (10.8%)
0.933

    multiple drug
17 (10.6%)
5 (6.2%)
22 (9.1%)
0.263
10 (8.4%)
0.829

Intubation

    single drug
8 (7.2%)
9 (15.0%)
17 (9.9%)
0.104
8 (7.8%)
0.561

    multiple drug
9 (5.6%)
9 (11.1%)
18 (7.4%)
0.122
8 (6.7%)
0.805

Vasopressor use

    single drug
5 (4.5%)
1 (1.7%)
6 (3.5%)
0.666
7 (6.9%)
0.245

    multiple drug
12 (7.5%)
4 (4.9%)
16 (6.6%)
0.588
4 (3.4%)
0.204

Mortality

    single drug
3 (2.7%)
0 (0%)
3 (1.8%)
0.553
1 (1.0%)
>0.999

    multiple drug
4 (2.5%)
1 (1.2%)
5 (2.1%)
0.667
1 (0.8%)
0.668

Hospital admission

    single drug
49 (44.1%)
30 (50.0%)
79 (46.2%)
0.464
33 (32.4%)
0.024

    multiple drug
63 (39.1%)
37 (45.7%)
100 (41.3%)
0.329
33 (24.8%)
0.012

ICU admission

    single drug
2 (1.8%)
7 (11.7%)
9 (5.3%)
0.010
16 (15.7%)
0.004

    multiple drug
10 (6.2%)
5 (6.2%)
15 (6.2%)
0.991
14 (11.8%)
0.067

Number of patients

    single drug
111
60
171

102

    multiple drug
161
81
242

119

GCS: Glasgow Coma Scale; ICU: intensive care unit.

noncharcoal and charcoal.

†Between charcoal-available and charcoal-unavailable period.

3.5. Presenting Time and Clinical Outcome according to Activated Charcoal Availability

Higher hospital admission rates and lower ICU admission rates during the charcoal-unavailable period also were observed among the patients with a time delay of more than 1 hour from ingestion to ED visit (Table 6). The other clinical outcomes did not differ between the periods. During the charcoal-available period, intubations were more commonly conducted for patients who had arrived at the ED within 1 hour and received activated charcoal (11.4 versus 9.1%, p = 0.015) (Table 6).

Table 6: Time delay from drug ingestion to ED visit and clinical outcome between charcoal-available and charcoal-unavailable periods.

Charcoal-available period
Charcoal-unavailable period
p-value†

Non-charcoal
Charcoal
Total
p

Aspiration pneumonia

    within 1hr
5 (7.6%)
3 (6.8%)
8 (7.3%)
1
5 (7.8%)
0.818

    over 1hr
23 (11.2%)
10 (10.3%)
33 (10.9%)
0.823
16 (10.2%)
>0.999

Intubation

    within 1hr
6 (9.1%)
5 (11.4%)
11 (10%)
0.015
3 (4.7%)
0.214

    over 1hr
11 (5.3%)
13 (13.4%)
24 (7.9%)
0.697
13 (8.3%)
0.893

Vasopressor use

    within 1hr
1 (1.5%)
0 (0%)
1 (0.9%)
1
3 (4.7%)
0.141

    over 1hr
16 (7.8%)
5 (5.2%)
21 (6.9%)
0.404
8 (5.1%)
0.443

Mortality

    within 1hr
0 (0%)
0 (0%)
0 (0%)
NA
0 (0%)
N/A

    over 1hr
7 (3.4%)
1 (1.0%)
8 (2.6%)
0.231
2 (1.3%)
0.506

Hospital admission

    within 1hr
17 (25.8%)
20 (45.5%)
37 (33.6%)
0.339
15 (23.4%)
0.156

    over 1hr
95 (46.1%)
47 (48.5%)
142 (46.9%)
0.171
51 (32.5%)
0.003

ICU admission

    within 1hr
3 (4.5%)
4 (9.1%)
7 (6.4%)
0.434
7 (10.9%)
0.285

    over 1hr
9 (4.4%)
8 (8.2%)
17 (5.6%)
0.171
23 (14.6%)
0.001

Number of patients

    within 1hr
66
44
110

64

    over 1hr
206
97
303

157

GCS: Glasgow Coma Scale; ICU: intensive care unit.

noncharcoal and charcoal.

†Between charcoal-available and charcoal-unavailable period.

3.6. Clinical Outcomes of Patients Who May Benefit from Activated Charcoal

Twenty-three patients and 17 patients were identified during the charcoal-available and charcoal-unavailable periods, respectively. Activated charcoal was used for 12 patients (52.1%) during the charcoal-available period. There were no differences in clinical outcomes between the periods (Table 7) (Supplemental Table 2).

Table 7: Clinical outcomes of patients who may benefit from activated charcoal use.

Charcoal-available period
Charcoal-unavailable period
p-value

n=23
n=17

Aspiration pneumonia, n (%)
2 (8.7%)
1 (5.9%)
0.615

Endotracheal intubation, n (%)
1 (4.3%)
1 (5.9%)
>0.999

Endotracheal intubation after 4 hours from ED visit, n (%)
1 (4.3%)
0 (0%)
>0.999

Vasopressor, n (%)
0 (0%)
2 (11.8%)
0.174

Vasopressor after 4 hours from ED visit, n (%)
0 (0%)
1 (5.9%)
0.436

Mortality, n (%)
0 (0%)
0 (0%)
NA

Hospital admission, n (%)
8 (34.8%)
5 (29.4%)
0.072

ICU admission, n (%)
1 (4.3%)
3 (17.6%)
0.294

Prolonged ICU admission
1 (4.3%)
1 (5.9%)
>0.999

ICU: intensive care unit.

: (1) present within 2 hours of acute overdose, (2) GCS 13-15 on arrival, and (3) potential toxic ingestion.

3.7. Mortality Cases

Among the mortality cases, only one patient visited within 2 hours of exposure. His age was 92 and he died due to aspiration pneumonia. Charcoal was not used, because of decreased consciousness, sedative poisoning, and high risk of respiratory complication. He died from respiratory complications 18 days from ED visit (Table 8). Other patients visited the ED 4 hours or more after exposure to toxins (Table 8).

Table 8: Summary of mortality cases.

Period
Sex
Age
Activated charcoal use
Time delay
Survival time
Toxic substances

Charcoal-available
male
92
-
2 hours
18 days
Sedatives

Charcoal-available
female
78
-
4 hours
2 days
Unidentified

Charcoal-available
male
29
-
17 hours
16 hours
Salicylate

Charcoal-available
female
66
-
8 hours
12 hours
Antidepressants

Charcoal-available
female
17
-
7 hours
7 hours
Bupropion

Charcoal-available
male
72
-
12 hours
1 days
Antipsychotics

Charcoal-available
female
70
-
6 hours
12 hours
Multiple drug including betablocker

Charcoal-available
male
56
+
4 hours
10 days
Multiple unidentified drugs including sedatives

Charcoal-unavailable
male
77
-
6 hours
4 days
Multiple antipsychotics

Charcoal-unavailable
male
61
-
4 hours
3 days
Unknown

4. Discussion

Activated charcoal has been used for the treatment of poisoned patients for more than 100 years and remains the major GI decontamination therapy for such cases [1, 2, 5, 14].

Many preclinical studies have shown beneficial effects of activated charcoal in various kinds of drug poisonings [5, 15–19]. However, few clinical studies have established any clinical benefits of activated charcoal use [1, 2, 5, 14]. One retrospective study showed activated charcoal within 2 hours of a paracetamol ingestion is associated with a decreased requirement for N-acetylcysteine [20]. A recent prospective study on massive paracetamol overdose found a benefit of activated charcoal use within 4 hours. Within that time, development of hepatotoxicity (peak ALT > 1000 U/L) was lower in the charcoal-treated patients. However, only serum liver enzyme levels were evaluated as an outcome and mortality, hospital day, presence and severity of hepatic encephalopathy, and liver transplantation were not [21].

Various clinical studies have failed to prove any clinical benefits of activated charcoal [8, 13, 22–24]. In a prospective ED study, there was no improvement of the clinical outcomes of single-dose activated charcoal. Activated charcoal use was associated with longer ED stay and higher incidence of vomiting. However, ICU admission, length of ICU and hospital stay, length of intubation time, and development of aspiration pneumonia were found to be unrelated to activated charcoal use [13]. One recent prospective study showed that age was the only factor associated with clinical improvement in case of drug poisoning, activated charcoal administration was determined to be unrelated to clinical outcome [24].

The reasons for the discrepancies between the results of preclinical and clinical studies are not clear. The risk of charcoal-induced aspiration might be one explanation. Chemical pneumonitis due to direct charcoal exposure is a fatal complication and has been, to say the least, a major concern [5, 25–29]. Development of aspiration pneumonitis in overdose patients has been related to poor prognosis [10, 11]. Activated charcoal use in instance of nonintubation and decreased mental status has been related to aspiration pneumonia [10]. However, other clinical studies have shown minimal risk of aspiration pneumonitis and pneumonia in the use of activated charcoal [30–32]. One retrospective study found that the incidence of pulmonary aspiration was only 0.6% in patients who had received multiple doses of activated charcoal [30]. An analysis of a toxicology-unit admission cohort showed a prevalence of aspiration pneumonitis of 11% and established that the predictors did not include activated charcoal use but rather age, emesis, and time delay from ingestion to hospital [32].

It is well known that airway protection is important for prevention of aspiration pneumonitis in poisoned patients [9]. The current guidelines emphasize airway protection prior to activated charcoal use [1, 2, 5]. In our study, intubations also were conducted more frequently for charcoal-administered patients (18, 51.4%) than for not-administered patients (17, 6.3%) (p = 0.024) in the charcoal-available period.

In our study, mortality, need of vasopressor, intubation, and incidence of aspiration pneumonia were not affected by charcoal availability (Table 3). Within the charcoal-available period, aspiration pneumonia developed in 13 (9.2%) of the charcoal-administered patients and 28 (10.3%) of the not-administered patients, of which difference was not significant (p = 0.729).

The ICU admission rate was increased in the charcoal-unavailable periods. However, the total hospital admission rate was lower (Table 3). For patients admitted to ICU, the number of ICU days and total hospital days were shorter in the charcoal-unavailable period (5 [3–10] versus 2 [1–5], p = 0.010 and, 10 [4–19] versus 4 [3–9], p = 0.021, respectively) (Figure 1). Because ICU days were shorter in the charcoal-unavailable period, the increase in the ICU admission rate might have been the result of concerns about activated charcoal unavailability.

In our study, most of the deaths occurred when the visit to the ED was delayed (Table 8). Delayed ED presentation can cause worsening of poisoning [33]. Early adequate supportive care seems to be a more cardinal treatment process than activated charcoal use.

The rate of activated charcoal use was high in charcoal-available period (34.1%). Nearly half (42%) of patients received the activated charcoal more than 2 hours after exposure to toxins. A Norwegian study reported 16% activated charcoal use for all admitted acute-poisoning patients in Oslo [34, 35]. However, our study also showed a low mortality rate in both the charcoal-available and charcoal-unavailable periods. These findings indirectly show that adequate supportive care is essential to the treatment of oral drug poisoned patients.

There are several limitations to this study. First, it is a retrospective study. Neither randomization or nor blinding was applied, and clinical decisions might have been affected by charcoal-availability. Second, the severity of poisoning was not high; the total mortality was only 1.6% (10 patients). Considering that activated charcoal is more beneficial for severe poisoning, its effect might have been underestimated [1, 2]. High mortality was observed among the delayed ED visit patients. Third, we included only adult patients and oral drug poisonings other than from plants, mushrooms, herbicides, and pesticides. Fourth, gastric lavage was used as a GI decontaminating agent in both periods and which can attenuate the clinical effects of charcoal unavailability. Finally, the exact substances or amounts could not be identified in many cases and thus were not fully evaluated in this study.

5. Conclusions

Between the charcoal-available and charcoal-unavailable periods, activated charcoal availability was unrelated to mortality, incidence of aspiration pneumonia, intubation, or use of vasopressor for treatment of oral drug poisoned patients.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

None of the authors has any financial or personal relationships with people or organizations that could inappropriately influence this study.

Supplementary Materials

Supplemental Table : time delay from drug exposure to presentation. Supplemental Table : major toxic agents of patients who may benefit from activated charcoal. NSAID: Nonsteroidal Anti-Inflammatory Drugs. : (1) present within 2 hours of acute overdose, (2) GCS 13-15 on arrival, and (3) potential toxic ingestion. (Supplementary Materials)

References

K. R. Olson, “Activated charcoal for acute poisoning: one toxicologist's journey,” Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology, vol. 6, no. 2, pp. 190–198, 2010.

G. K. Isbister and V. V. Kumar, “Indications for single-dose activated charcoal administration in acute overdose,” Current Opinion in Critical Care, vol. 17, no. 4, pp. 351–357, 2011.

E. M. Caravati and B. Mégarbane, “Update of position papers on gastrointestinal decontamination for acute overdose,” Clinical Toxicology, vol. 51, no. 3, pp. 127–127, 2013.

D. D. Gummin, J. B. Mowry, D. A. Spyker, D. E. Brooks, M. O. Fraser, and W. Banner, “2016 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 34th Annual Report,” Clinical Toxicology, vol. 55, no. 10, pp. 1072–1254, 2017.

P. A. Chyka and D. Seger, “Position paper: single-dose activated charcoal,” Journal of Toxicology, vol. 43, no. 2, pp. 61–87, 2005.

S. M. Reid, G. M. Neto, T. J. Clifford, N. Randhawa, and A. Plint, “Use of single-dose activated charcoal among Canadian pediatric emergency physicians,” Pediatric Emergency Care, vol. 22, no. 10, pp. 724–728, 2006.

G. Corcoran, B. Chan, and A. Chiew, “Use and knowledge of single dose activated charcoal: A survey of Australian doctors,” EMA - Emergency Medicine Australasia, vol. 28, no. 5, pp. 578–585, 2016.

J. Moon, B. Chun, and K. Song, “An exploratory study; the therapeutic effects of premixed activated charcoal–sorbitol administration in patients poisoned with organophosphate pesticide,” Clinical Toxicology, vol. 53, no. 2, pp. 119–126, 2015.

J. Moll, W. Kerns II, C. Tomaszewski, and R. Rose, “Incidence of aspiration pneumonia in intubated patients receiving activated charcoal,” The Journal of Emergency Medicine, vol. 17, no. 2, pp. 279–283, 1999.

J. Liisanantti, P. Kaukoranta, M. Martikainen, and T. Ala-Kokko, “Aspiration pneumonia following severe self-poisoning,” Resuscitation, vol. 56, no. 1, pp. 49–53, 2003.

A. Christ, C. A. Arranto, C. Schindler et al., “Incidence, risk factors, and outcome of aspiration pneumonitis in ICU overdose patients,” Intensive Care Medicine, vol. 32, no. 9, pp. 1423–1427, 2006.

S. Beaune, P. Juvin, A. Beauchet, E. Casalino, and B. Megarbane, “Deliberate drug poisonings admitted to an emergency department in Paris area - A descriptive study and assessment of risk factors for intensive care admission,” European Review for Medical and Pharmacological Sciences, vol. 20, no. 6, pp. 1174–1179, 2016.

K. S. Merigian and K. E. Blaho, “Single-dose oral activated charcoal in the treatment of the self-poisoned patient: a prospective, randomized, controlled trial.,” American Journal of Therapeutics, vol. 9, no. 4, pp. 301–308, 2002.

D. N. Juurlink, “Activated charcoal for acute overdose: a reappraisal,” British Journal of Clinical Pharmacology, vol. 81, no. 3, pp. 482–487, 2016.

G. R. Bond, “The role of activated charcoal and gastric emptying in gastrointestinal decontamination: A state-of-the-art review,” Annals of Emergency Medicine, vol. 39, no. 3, pp. 273–286, 2002.

W. N. Glab, D. G. Corby, W. J. Decker, and V. R. Coldiron, “Decreased absorption of propoxyphene by activated charcoal,” Clinical Toxicology, vol. 19, no. 2, pp. 129–138, 1982.

A. L. Picchioni, L. Chin, and T. Gillespie, “Evaluation of activated charcoal-sorbitol suspension as an antidote,” Clinical Toxicology, vol. 19, no. 5, pp. 433–444, 1982.

G. Jürgens, L. C. Groth Hoegberg, and N. A. Graudal, “The effect of activated charcoal on drug exposure in healthy volunteers: a meta-analysis,” Clinical Pharmacology & Therapeutics, vol. 85, no. 5, pp. 501–505, 2009.

M. Mullins, B. R. Froelke, and M. R.-P. Rivera, “Effect of delayed activated charcoal on acetaminophen concentration after simulated overdose of oxycodone and acetaminophen,” Clinical Toxicology, vol. 47, no. 2, pp. 112–115, 2009.

N. A. Buckley, I. M. Whyte, D. L. O'Connell, and A. H. Dawson, “Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose,” Journal of Toxicology - Clinical Toxicology, vol. 37, no. 6, pp. 753–757, 1999.

A. L. Chiew, G. K. Isbister, K. A. Kirby, C. B. Page, B. S. H. Chan, and N. A. Buckley, “Massive paracetamol overdose: an observational study of the effect of activated charcoal and increased acetylcysteine dose (ATOM-2),” Clinical Toxicology, vol. 55, no. 10, pp. 1055–1065, 2017.

M. Eddleston, E. Juszczak, N. A. Buckley et al., “Multiple-dose activated charcoal in acute self-poisoning: a randomised controlled trial,” The Lancet, vol. 371, no. 9612, pp. 579–587, 2008.

K. Cumpston, P. Stromberg, B. K. Wills, and S. R. Rose, “Activated charcoal does not reduce duration of phenytoin toxicity in hospitalized patients,” American Journal of Therapeutics, vol. 23, no. 3, pp. e773–e777, 2016.

G. Orfanidou, A. Chalkias, A. Koutsovasilis, G. Loizos, and T. Xanthos, “Activated charcoal may not be necessary in all oral overdoses of medication,” The American Journal of Emergency Medicine, vol. 34, no. 2, pp. 319–321, 2016.

D. G. Menzies, A. Busuttil, and L. F. Prescott, “Fatal pulmonary aspiration of oral activated charcoal.,” BMJ, vol. 297, no. 6646, pp. 459-460, 1988.

C. G. Elliott, T. V. Colby, T. M. Kelly, and H. G. Hicks, “Charcoal lung. Bronchiolitis obliterans after aspiration of activated charcoal,” CHEST, vol. 96, no. 3, pp. 672–674, 1989.

A. De Weerdt, A. Snoeckx, P. Germonpré, and P. G. Jorens, “Rapid-onset adult respiratory distress syndrome after activated charcoal aspiration. A pitch-black tale of a potential to kill,” American Journal of Respiratory and Critical Care Medicine, vol. 191, no. 3, pp. 344-345, 2015.

C. R. Harris and D. Filandrinos, “Accidental administration of activated charcoal into the lung: Aspiration by proxy,” Annals of Emergency Medicine, vol. 22, no. 9, pp. 1470–1473, 1993.

J. B. Hack, M. Gilliland, and W. J. Meggs, “Images in emergency medicine,” Annals of Emergency Medicine, vol. 48, no. 5, p. 522, 2006.

C. L. Dorrington, D. W. Johnson, and R. Brant, “The frequency of complications associated with the use of multiple-dose activated charcoal,” Annals of Emergency Medicine, vol. 41, no. 3, pp. 370–377, 2003.

A. O. Alaspää, M. J. Kuisma, K. Hoppu, and P. J. Neuvonen, “Out-of-hospital administration of activated charcoal by emergency medical services,” Annals of Emergency Medicine, vol. 45, no. 2, pp. 207–212, 2005.

G. K. Isbister, F. Downes, D. Sibbritt, A. H. Dawson, and I. M. Whyte, “Aspiration pneumonitis in an overdose population: Frequency, predictors, and outcomes,” Critical Care Medicine, vol. 32, no. 1, pp. 88–93, 2004.

D. G. Craig, C. M. Bates, J. S. Davidson, K. G. Martin, P. C. Hayes, and K. J. Simpson, “Staggered overdose pattern and delay to hospital presentation are associated with adverse outcomes following paracetamol-induced hepatotoxicity,” British Journal of Clinical Pharmacology, vol. 73, no. 2, pp. 285–294, 2012.

C. Lund, P. Drottning, B. Stiksrud et al., “A one-year observational study of all hospitalized acute poisonings in Oslo: complications, treatment and sequelae,” Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine , vol. 20, article no. 49, 2012.

C. Lund, B. Teige, P. Drottning et al., “A one-year observational study of all hospitalized and fatal acute poisonings in Oslo: Epidemiology, intention and follow-up,” BMC Public Health, vol. 12, no. 1, 2012.